Bharat Biotech’s intranasal vaccine for COVID-19

Bharat Biotech’s intranasal vaccine for COVID-19

Recently, Bharat Biotech has completed the Phase II trial of the intranasal (injected through the nose) Covid vaccine, BBV 154.

It is a novel adeno virus carrier vaccine.

Profit:

Other vaccines only produce antibodies, but intranasal vaccines produce antibodies as well as reduce the risk of infection.

Easy dispensing – no syringe and needle required.

Additional immune response:

  • In addition to immunity in the blood, it also activates the immunity of cells found in the tissues of the nose and mouth and lungs.
  • Only a small amount of this will usually be needed, usually 0.1 ml.

Source – PIB

Download Our App

More Current Affairs

Share with Your Friends

Join Our Whatsapp Group For Daily, Weekly, Monthly Current Affairs Compilations

Related Articles

Youth Destination Facilities